- Home
- CNSP vs GTBP Comparison
CNSP vs GTBP Comparison
Compare CNSP & GTBP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CNSP
- GTBP
- Stock Information
- Founded
- CNSP 2017
- GTBP 1965
- Country
- CNSP United States
- GTBP United States
- Employees
- CNSP N/A
- GTBP N/A
- Industry
- CNSP Biotechnology: Pharmaceutical Preparations
- GTBP Biotechnology: Pharmaceutical Preparations
- Sector
- CNSP Health Care
- GTBP Health Care
- Exchange
- CNSP Nasdaq
- GTBP Nasdaq
- Market Cap
- CNSP 5.6M
- GTBP 5.5M
- IPO Year
- CNSP 2019
- GTBP N/A
- Fundamental
- Price
- CNSP $0.82
- GTBP $3.14
- Analyst Decision
- CNSP Hold
- GTBP Strong Buy
- Analyst Count
- CNSP 1
- GTBP 1
- Target Price
- CNSP N/A
- GTBP $11.00
- AVG Volume (30 Days)
- CNSP 212.8K
- GTBP 76.2K
- Earning Date
- CNSP 08-13-2025
- GTBP 08-13-2025
- Dividend Yield
- CNSP N/A
- GTBP N/A
- EPS Growth
- CNSP N/A
- GTBP N/A
- EPS
- CNSP N/A
- GTBP N/A
- Revenue
- CNSP N/A
- GTBP N/A
- Revenue This Year
- CNSP N/A
- GTBP N/A
- Revenue Next Year
- CNSP N/A
- GTBP N/A
- P/E Ratio
- CNSP N/A
- GTBP N/A
- Revenue Growth
- CNSP N/A
- GTBP N/A
- 52 Week Low
- CNSP $0.73
- GTBP $1.72
- 52 Week High
- CNSP $148.00
- GTBP $4.10
- Technical
- Relative Strength Index (RSI)
- CNSP 39.83
- GTBP 52.68
- Support Level
- CNSP $0.73
- GTBP $2.75
- Resistance Level
- CNSP $0.90
- GTBP $3.73
- Average True Range (ATR)
- CNSP 0.07
- GTBP 0.27
- MACD
- CNSP 0.01
- GTBP 0.01
- Stochastic Oscillator
- CNSP 46.48
- GTBP 35.45
About CNSP CNS Pharmaceuticals Inc.
CNS Pharmaceuticals Inc is a clinical-stage pharmaceutical company focused on the development of anticancer drug candidates for the treatment of primary and metastatic brain and central nervous system tumors. It is involved in the development of Berubicin, which is a therapy for the treatment of glioblastoma. Glioblastomas are tumors that arise from astrocytes, which are star-shaped cells that make up the supportive tissue of the brain.
About GTBP GT Biopharma Inc.
GT Biopharma Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel immuno-oncology products in the United States. It is engaged in discovering, developing, and commercializing novel therapeutics from its proprietary product platform in a varied range of disease areas. The company mainly develops drugs focused on the treatment of cancer. Its TriKE (Tri-specific Killer Engager) platforms offer immuno-oncology products that can treat a range of hematologic malignancies, sarcoma, and solid tumors.